Stocks · Healthcare · Biotechnology
BioCryst Pharmaceuticals, Inc. BCRX
$8.10 -0.86% Close, Oct 5, 2026 · NASDAQ · Market cap $2.08B
Strong growthLow risk
Next earnings report: Nov 2, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -33.3% from 9.7% a year earlier.
- The diluted share count rose 20.6% in a year.
- Revenue over the last four quarters was $940.6M, up 68.7% from a year earlier, slowing from 75.9% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 13%
- FCF growth (TTM, YoY)Top 1%
- Revenue growth, 3-year CAGRTop 14%
- Revenue growth accelerationBottom 21%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 12%
- Gross marginBottom 16%
- Operating marginBottom 39%
- Accruals (lower is better)Top 1%
- Interest coverBottom 43%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 35%
- Free-cash-flow yieldTop 3%
- EBITDA / enterprise valueBottom 36%
- Sales / enterprise valueTop 31%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 38%
- 6-month returnBottom 27%
- 1-year return vs S&P 500Bottom 49%
- Distance from 52-week highTop 44%
- Trend checklist (0–4)Bottom 36%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 47%
- Upside to consensus price targetTop 29%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 29%
- Maximum drawdown, 3 yearsTop 19%
- Beta vs S&P 500 (lower is better)Top 19%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 75.9% | 68.7% | ↓ |
| Gross margin | 97.0% | 23.5% | ↓ |
| Operating margin | 9.7% | -33.3% | ↓ |
| FCF margin | 2.8% | 38.0% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 68.7% | 75.9% | ↓ | Top 13% |
| Gross margin | 23.5% | 97.0% | ↓ | Bottom 16% |
| Operating margin | -33.3% | 9.7% | ↓ | Bottom 39% |
| Net margin | -40.9% | -6.4% | ↓ | — |
| Free-cash-flow margin | 38.0% | 2.8% | ↑ | — |
| Return on invested capital | -89.0% | — | Bottom 12% | |
| Revenue growth, 3-year CAGR | 47.8% | — | Top 14% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -133.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 13.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -47.2 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -4.2×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.40%
- Shareholder yield
- -1.40%
- Share count change, 1 year
- +20.6%
- Share count change, 3-year CAGR
- +11.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +0.9%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $19.00
- Target vs current price
- +134.6%
- Analysts with a rating
- 29
- Share rating Buy or Strong Buy
- 79%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +94.6% | +0.6% | +14.6% | +10.0% | — |
| May 6, 2026 | -5066.7% | -2.2% | -2.5% | -8.6% | -0.6% |
| Feb 26, 2026 | +1500.0% | +4.6% | +13.5% | +24.5% | +10.9% |
| Nov 3, 2025 | -14.3% | -6.3% | -3.1% | -2.6% | -8.9% |
| Aug 4, 2025 | -33.3% | +9.8% | +4.4% | +4.5% | -8.1% |
| May 5, 2025 | +100.2% | +23.5% | +11.6% | +20.2% | -8.0% |
| Feb 24, 2025 | -85.7% | -10.0% | -6.5% | -13.4% | +12.6% |
| Nov 4, 2024 | +0.0% | -12.8% | -7.7% | -12.5% | -6.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | $0.30 | $0.15 | +94.6% | $218.3M |
| May 6, 2026 | -$2.98 | $0.06 | -5066.7% | $156.4M |
| Feb 26, 2026 | $1.12 | $0.07 | +1500.0% | $406.6M |
| Nov 3, 2025 | $0.06 | $0.07 | -14.3% | $159.4M |
| Aug 4, 2025 | $0.02 | $0.03 | -33.3% | $163.4M |
| May 5, 2025 | $0.00 | -$0.07 | +100.2% | $145.5M |
| Feb 24, 2025 | -$0.13 | -$0.07 | -85.7% | $131.5M |
| Nov 4, 2024 | -$0.07 | -$0.07 | +0.0% | $117.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 2.48× | — | — | Top 31% |
| Free-cash-flow yield | 17.20% | — | — | Top 3% |
| Earnings yield | -18.53% | — | — | Bottom 35% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -5.6%
- 200-day average slope (20 days)
- +1.3%
- Distance from 50-day average
- -11.9%
- Distance from 200-day average
- -6.7%
- RSI (14)
- 34.8
- Relative volume
- 0.79×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 44.9%
- Volatility vs own 5-year history
- 14th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.56
- Correlation with S&P 500
- 0.19
- Current drawdown from 1-year high
- -27.1%
- Maximum drawdown, 3 years
- -46.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 16, 2022 | Apr 30, 2024 | -79.1% | 552 days | Not yet recovered |
| Aug 9, 2021 | Dec 6, 2021 | -36.7% | 83 days | 45 days (Feb 9, 2022) |
| Mar 10, 2021 | Apr 12, 2021 | -30.2% | 22 days | 25 days (May 17, 2021) |
| Feb 1, 2021 | Feb 11, 2021 | -22.4% | 8 days | 11 days (Mar 1, 2021) |
| Dec 18, 2020 | Dec 29, 2020 | -18.2% | 6 days | 12 days (Jan 15, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $2.08B
- EPS, diluted (TTM)
- -$1.50
- Revenue (TTM)
- $940.6M
- 52-week range
- $6.00 – $11.22
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Gross profit | $149.9M | $264.2M | $326.8M | $438.2M | $855.8M |
| Operating income | -$177.7M | -$148.4M | -$103.7M | -$2.5M | $341.0M |
| Net income | -$184.1M | -$247.1M | -$226.5M | -$88.9M | $263.9M |
| EPS (diluted) | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $117.1M | $131.5M | $145.5M | $163.4M | $159.4M | $406.6M | $156.4M | $218.3M |
| Net income | -$14.0M | -$26.8M | $32,000 | $5.1M | $12.9M | $245.8M | -$721.8M | $78.4M |
| EPS (diluted) | -$0.07 | -$0.13 | $0.00 | $0.02 | $0.06 | $1.12 | -$2.98 | $0.30 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$142.2M | -$161.8M | -$95.1M | -$52.0M | $329.9M |
| Capital expenditure | -$2.4M | -$1.4M | -$2.2M | -$1.1M | -$2.5M |
| Free cash flow | -$144.5M | -$163.2M | -$97.3M | -$53.1M | $327.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $50.1M | $190,000 | $342,000 | $34,000 | $9.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $352.6M
- Total assets
- $557.9M
- Total liabilities
- $1.01B
- Total debt
- $409.9M
- Net debt
- $254.9M
- Shareholders’ equity
- -$454.3M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 34,868,460
- Days to cover
- 7.29
- Change vs previous report
- +2.4%
FINRA short interest, settlement date Sep 15, 2026.